Skip to main content

Further to WPQ 20208, what actions, if any, will be taken if post-implementation monitoring shows Māori access has declined or complication rates have increased?

Answered Question 28189 (2026)
Question published
Reply lodged
Bookmark

Asked by

Debbie Ngarewa-Packer

Member for Te Tai Hauāuru · Te Pāti Māori

Question

  • Further to WPQ 20208, what actions, if any, will be taken if post-implementation monitoring shows Māori access has declined or complication rates have increased?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

I am advised that Pharmac will monitor post-change medicine uptake. I note that no one currently receiving empagliflozin, dulaglutide, or liraglutide for type 2 diabetes would lose access, and the proposed changes would apply to new applications only.